Emergent Health Stock Price, News & Analysis

Emergent Health Corp. (OTC PINK: EMGE) has acquired Regen Biowellness, Inc., expanding its footprint in the plant-based and regenerative medical sectors. The deal involves the issuance of preferred stock and other financial considerations. Industry veteran Jim Morrison, former L'Oréal President, joins Emergent's Board of Directors. This acquisition aims to bolster the company's product portfolio in both human and pet health, focusing on regenerative medicine and OTC products, while leveraging Morrison's extensive industry experience.

Emergent Health Corp. (OTC PINK:EMGE) has retained Imagemme, a leading branding studio, to develop its new brand, "The Wholistic Company". This initiative aims to unify its health, wellness, and regenerative products and establish effective marketing strategies for multi-channel sales. The company plans to complete acquisitions of Regen Biowellness, Evolutionary Biologics, and Fusion Specialty Pharmacies by August 2022. CEO James W. Zimbler expresses optimism for the brand's potential to become a household name.

Emergent Health Corp. (OTC PINK:EMGE) announces its acquisition of Evolutionary Biologics, specializing in regenerative biological products. The partnership with By Design Medical aims to commercially launch their flagship product, Exo Elixir TM, a regenerative serum derived from dermal fibroblast stem cells. The biologics market is projected to grow from US $366.43 billion in 2021 to over US $719.84 billion by 2030. The acquisition is expected to finalize within two weeks, enhancing Emergent's market position in aesthetics and regenerative medicine.

Emergent Health Corp. (OTC PINK:EMGE) is set to acquire Regen Biowellness, Inc., a distributor in the plant-based and regenerative medical fields, with the acquisition expected to close around August 1, 2022. The acquisition follows Regen's recent resolution of its bankruptcy litigation. Jim Morrison, former President of L'Oréal, will join Emergent's Board and serve as CEO post-acquisition. This acquisition aims to expand Emergent's portfolio in the wellness sector, including human and pet products, enhancing growth and shareholder value.

Emergent Health Corp. (OTC PINK:EMGE) has signed a Letter of Intent to acquire Evolutionary Biologics, Inc., focusing on regenerative products like Evo Hybrid and HydrEyes. The transaction involves equity issuance and capital investment to enhance sales and operations. Former L'Oréal President Jim Morrison will assume the role of full-time CEO. This acquisition aims to position Emergent as a leader in plant-based wellness and regenerative health, targeting consumer awareness through innovative marketing strategies.

Emergent Health Corp. (OTC PINK:EMGE) announces its expected acquisition of Regen Biowellness, aiming to re-launch the FDA Registered Immune Booster supplement ImmunaZin™. This supplement, featuring a unique blend of 44 amino acid fragments, enhances T helper cell production to combat pathogens. Emergent plans to partner with wholesale and multi-level marketing firms for distribution and is set to introduce ImmunaZin™ in Q4 2022. The merger aims to position Emergent-Regen as a leader in the plant-based wellness sector.

Emergent Health Corp. (OTC PINK: EMGE) has announced a joint venture with Nutralife Biosciences to co-produce and market nutraceutical products. Nutralife, a seasoned player in the nutraceutical and skincare industry, will enhance Emergent's distribution capabilities through its established production and marketing platforms. This partnership is expected to boostEmergent's reach in the health and wellness sector and enhance the availability of its PharmaZu pet products. The official launch of PharmaZu's website is set for August 15, 2022.

Emergent Health Corp. (OTC PINK:EMGE) announced a Letter of Intent to acquire Regen Biowellness, Inc., expanding its portfolio in the plant-based and regenerative medical fields. Jim Morrison, former President of L'Oréal, will join Emergent's management team. The deal aims to integrate Regen's patent-protected products including Immuniain™ and various cannabinoid compositions into Emergent's offerings. The acquisition is expected to close by mid-to-end July 2022, following the dismissal of Regen's bankruptcy petition.

Emergent Health Corp. (OTC PINK:EMGE) has executed a Binding Letter of Intent to acquire Fusion Specialty Pharmacy, pending financing and definitive agreements. In 2021, Fusion reported revenues of $3,801,497, reflecting a near 100% increase from 2020. This acquisition aims to close in the 3rd quarter of 2022, enabling Emergent to expand its online pet medication services through PharmaZu, Inc., and to enhance its operational capabilities across all states.